First real-world evidence (RWE) results documented no enhanced adverse effects when VA was given in addition to PD-1/PD-L1 inhibitor therapy in patients with advanced or metastasised melanoma or lung cancer [48,49,50,51]. Here, CD274 is linked to lung cancer.